Class summary at a glance.

Every drug in the Neurokinin 3 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $70.1Mcombined across class
Total Rx claims: 99K29K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Fezolinetant

Brand: VEOZAH · 99K Part D claims (CY24) · 29K beneficiaries · First FDA approval: 2023-05-12

Brand-only (no generics) 170 plans require PA

Low NADAC$18.63

→

Avg plan cost$18.63

Part D spend $70.1M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.